Ameriprise Financial Inc. bought a new stake in Versartis, Inc. (NASDAQ:VSAR) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 87,690 shares of the biopharmaceutical company’s stock, valued at approximately $1,530,000. Ameriprise Financial Inc. owned about 0.25% of Versartis at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. First Quadrant L P CA purchased a new position in shares of Versartis in the 2nd quarter valued at approximately $155,000. Bank of America Corp DE boosted its stake in shares of Versartis by 46.3% in the first quarter. Bank of America Corp DE now owns 9,482 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 3,001 shares in the last quarter. UBS Group AG purchased a new stake in shares of Versartis in the first quarter valued at approximately $367,000. Russell Investments Group Ltd. boosted its stake in shares of Versartis by 125.9% in the first quarter. Russell Investments Group Ltd. now owns 18,160 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 10,121 shares in the last quarter. Finally, American International Group Inc. boosted its stake in shares of Versartis by 20.7% in the first quarter. American International Group Inc. now owns 18,962 shares of the biopharmaceutical company’s stock valued at $405,000 after buying an additional 3,250 shares in the last quarter. Institutional investors own 73.61% of the company’s stock.

A number of analysts recently weighed in on the company. ValuEngine downgraded Versartis from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. Piper Jaffray Companies downgraded Versartis from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $26.00 to $4.00 in a research note on Friday, September 22nd. Barclays PLC downgraded Versartis from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $28.00 to $4.00 in a research note on Friday, September 22nd. Citigroup Inc. downgraded Versartis from a “buy” rating to a “neutral” rating and decreased their price target for the company from $23.00 to $3.00 in a research note on Monday, September 25th. Finally, BidaskClub downgraded Versartis from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. One analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $7.22.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/ameriprise-financial-inc-takes-1-53-million-position-in-versartis-inc-vsar/1679749.html.

Versartis, Inc. (NASDAQ VSAR) opened at $1.85 on Friday. Versartis, Inc. has a 1-year low of $1.70 and a 1-year high of $24.00. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 0.09.

Versartis (NASDAQ:VSAR) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.78). During the same period in the previous year, the business earned ($0.92) earnings per share. research analysts predict that Versartis, Inc. will post -4.06 earnings per share for the current fiscal year.

In related news, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of Versartis stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $3.29, for a total transaction of $7,007,700.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 2,132,769 shares of company stock valued at $7,014,761. 10.90% of the stock is currently owned by insiders.

Versartis Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Want to see what other hedge funds are holding VSAR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versartis, Inc. (NASDAQ:VSAR).

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.